Drugs / 3,4-methylenedioxymethamphetamine
3,4-methylenedioxymethamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05837845 | Feb 2025 → May 2027 expected | post-traumatic stress disorder | Patricia Suppes | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine | “MDMA-assisted cognitive processing therapy (MDMA-aCPT) is a novel treatment package that combines standard CPT with the administration of MDMA...” NCT05837845 ↗ |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05837845 ↗ |
| Known as | MDMA HCl | “Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions” NCT05837845 ↗ |